Bringing our test to healthcare providers and patients

The PATHFINDER Study is a prospective, interventional, multi-center study evaluating the implementation of an earlier version of Galleri in clinical practice. This is the first time our test has been used to return results to healthcare providers and communicated to participants to help guide appropriate diagnostic workups, and evaluate how these test results affect diagnostic and care pathways in a screening population.

The study enrolled approximately 6,600 participants, who will be followed for 12 months from the time of their enrollment.

Galleri: GRAIL’s multi-cancer early detection test

The Galleri test is designed to detect multiple types of cancer through a single blood draw by looking for signals of cancer that may be present. If a signal that may be cancer is detected, Galleri is designed to identify the location in the body where the signal may be coming from, for example, the pancreas or the lungs. This information is intended to help healthcare providers determine the appropriate test(s) to confirm whether cancer is present.

Thank you for your contribution

GRAIL and its collaborators would like to extend a big thank you to all the participants who contributed to the PATHFINDER Study. Your participation is bringing GRAIL and its collaborators one step closer to bringing Galleri into the hands of patients and healthcare providers.